DEC 02, 2021 3:00 AM PST

A New Method to Enhance Immunotherapy in Mouse Tumors

WRITTEN BY: Katie Kokolus

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, accounting for about 90% of pancreatic cancer diagnoses.  PDAC tumors are highly immunosuppressive, which means they evade mechanisms of the immune system.  Therefore, these tumors are very aggressive, and treatment options are limited.

Immune checkpoint inhibitors (ICI) are immunotherapy drugs that block the binding of immune checkpoints with their partner proteins. Under normal conditions, immune checkpoints regulate the immune response to prevent autoimmune responses.  However, the blockade provided by ICIs prevents the checkpoints from turning down the activity of cancer-killing immune cells.  Thus, the use of ICIs promotes and extends the anti-cancer activities of immune cells.

Unfortunately, the immunosuppressive nature of PDAC, along with the low number of immune cells which typically enter the tumor, ICIs fail to control tumor growth.  Tumors that exhibit these characteristics are sometimes called “cold” tumors because they do not initiate a robust immune response.  Alternatively, “hot” tumors exhibit strong immune activity and are usually filled with many anti-cancer immune cells.  Because hot tumors respond to ICIs much more efficiently than cold tumors, there is a critical need to develop therapeutic methods which turn cold tumors hot

A study published in the Journal for Immunotherapy of Cancer demonstrates a novel method of sensitizing mouse tumors to the popular ICI anti-PD-1. The study utilizes a drug that inhibits a protein called dipeptidyl peptidase (DPP).

The research team administered an oral DPP inhibitor to mice with PDAC tumors.  Using a variety of immunological techniques, the researchers examined how DDP inhibition altered the immune status of the tumors.  The study demonstrated that anti-tumor immune cells, including natural kills (NK) cells and T cells.  The increased immune cell infiltration was accompanied by slowed tumor growth and improved efficacy of anti-PD-1 therapy. 

Importantly, mice treated with combination therapy consisting of DPP and PD-1 inhibition developed immune memory demonstrated by rejection of tumors following re-exposure.  This finding suggests that this combination therapy could potentially protect from cancer recurrence.

The authors summarize that their study underscores the importance of DPPs in PDAC development.   They also conclude that DPP inhibition enhances natural anti-tumor immunity and ICI effectiveness in mouse models of PDAC.  The data presents a strong rationale for exploring clinical development of a combination DPP/PD-1 inhibition strategy. 

Sources: PDAC, ICI, cold, hot, turn cold tumors hot, Journal for ImmunoTherapy of Cancer, PD-1, DPP, NK, T cells

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
OCT 07, 2021
Cancer
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
OCT 07, 2021
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
Neuroblastoma is a cancer of immature nerve cells found in various areas, including the adrenal glands, neck, chest ...
OCT 21, 2021
Cancer
Exercise: A Secret Weapon to Combat Prostate Cancer?
OCT 21, 2021
Exercise: A Secret Weapon to Combat Prostate Cancer?
Exercise oncology is an evolving science that considers the addition of physical activity regimens to the treatment ...
NOV 09, 2021
Immunology
Wikipedia, but Make It Immune Cells
NOV 09, 2021
Wikipedia, but Make It Immune Cells
Scientists have established the first searchable database of complex immune data, providing the foundations for a new er ...
DEC 06, 2021
Cancer
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
DEC 06, 2021
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
The most common form of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). DLBCL is a fast-growing cancer th ...
DEC 27, 2021
Cancer
Improving Immunotherapy with a Novel Nanoparticle
DEC 27, 2021
Improving Immunotherapy with a Novel Nanoparticle
Malignant pleural effusion (MPE) occurs in cancer patients experiencing a buildup of fluid and tumor cells in the pleura ...
Loading Comments...